Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Paul Nyandoto"'
Autor:
Pia Osterlund, Tapio Salminen, MD, Leena-Maija Soveri, MD, Raija Kallio, MD, Ilmo Kellokumpu, MD, Annamarja Lamminmäki, MD, Päivi Halonen, MD, Raija Ristamäki, MD, Eila Lantto, MD, Aki Uutela, MD, Emerik Osterlund, MD, Ali Ovissi, MD, Arno Nordin, MD, Eetu Heervä, MD, Kaisa Lehtomäki, MD, Jari Räsänen, MD, Maija Murashev, MD, Laura Aroviita, MD, Antti Jekunen, Prof, Reneé Lindvall-Andersson, MD, Paul Nyandoto, MD, Juha Kononen, MD, Anna Lepistö, MD, Tuija Poussa, MSc, Timo Muhonen, MD, Annika Ålgars, MD, Helena Isoniemi, Prof
Publikováno v:
The Lancet Regional Health. Europe, Vol 3, Iss , Pp 100049- (2021)
Background: Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. Methods: A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the
Externí odkaz:
https://doaj.org/article/242b5d11ce0240999caa17287c9963a7
Autor:
Kaisa Lehtomäki, Leena-Maija Soveri, Emerik Osterlund, Annamarja Lamminmäki, Aki Uutela, Eetu Heervä, Päivi Halonen, Hanna Stedt, Sonja Aho, Timo Muhonen, Annika Ålgars, Tapio Salminen, Raija Kallio, Arno Nordin, Laura Aroviita, Paul Nyandoto, Juha Kononen, Bengt Glimelius, Raija Ristamäki, Helena Isoniemi, Pia Osterlund
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 10; Pages: 3541
Older adults are underrepresented in metastatic colorectal cancer (mCRC) studies and thus may not receive optimal treatment, especially not metastasectomies. The prospective Finnish real-life RAXO-study included 1086 any organ mCRC patients. We asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfd4a612da0a91a91ca4676569be72e6
Autor:
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola, Minna Tanner, Johan Ahlgren, Päivi Auvinen, Outi Lahdenperä, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Paula Poikonen-Saksela, Vesa Kataja, Petri Bono, Jouni Junnila, Henrik Lindman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(10)
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e957e9a0300b8b406a55981185af5662
https://pubmed.ncbi.nlm.nih.gov/35020465
https://pubmed.ncbi.nlm.nih.gov/35020465
Publikováno v:
Acta Oncologica. 60:687-691
A large autopsy study of 500,000 people reported the incidence of primary cardiac and pericardial tumors to be 0.0022% [1]. Primary pericardial mesothelioma (PPM) is a rare type of malignant mesenc...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eac5a5236e05a27184e21ef89abceb2
https://doi.org/10.1080/0284186x.2021.1887515
https://doi.org/10.1080/0284186x.2021.1887515
Autor:
Maija Murashev, Aki Uutela, Tuija Poussa, Ilmo Kellokumpu, Leena-Maija Soveri, T Muhonen, T. Salminen, Eila Lantto, Emerik Osterlund, are listed in Appendix Table B, Raija Ristamäki, P. Halonen, Paul Nyandoto, Pia Österlund, Annamarja Lamminmäki, Juha Kononen, A. Jekunen, Laura Aroviita, Helena Isoniemi, Ali Ovissi, Raija Kallio, Annika Ålgars, Anna Lepistö, Jari Räsänen, Eetu Heervä, Renee Lindvall-Andersson, Arno Nordin, Kaisa Lehtomäki
Publikováno v:
The Lancet Regional Health-Europe
The Lancet Regional Health. Europe, Vol 3, Iss, Pp 100049-(2021)
The Lancet Regional Health. Europe, Vol 3, Iss, Pp 100049-(2021)
Background Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. Methods A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8fe6bf5e84b9de724ab0f16459cbc3e
https://pubmed.ncbi.nlm.nih.gov/34557799
https://pubmed.ncbi.nlm.nih.gov/34557799
Autor:
Riikka Huovinen, Henrik Lindman, Päivi Auvinen, Pirkko-Liisa Kellokumpu-Lehtinen, Peter Canney, Judith Fraser, Oskar Johansson, Liisa Sailas, P. Halonen, Diana Ritchie, Teppo Huttunen, Meri Utriainen, Hans Wildiers, Taina Turpeenniemi-Hujanen, Paul Nyandoto, Kenneth Villman, Jeffrey Yachnin, Patrick Neven, Heikki Joensuu, Vernon Harvey, Helena Granstam-Bjorneklett, Lotta Lundgren, Minna Tanner
IMPORTANCE: Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. While the standard duration of trastuzumab treatment is 12 months, the benefi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c68dcbbc739ad072b62af0c87cf7af44
http://hdl.handle.net/10138/248394
http://hdl.handle.net/10138/248394
Autor:
P. Halonen, H Joensuu, Hans Wildiers, Jeffrey Yachnin, Kenneth Villman, Teppo Huttunen, Helena Granstam-Bjorneklett, V J Harvey, Meri Utriainen, Lotta Lundgren, Taina Turpeenniemi-Hujanen, Pirkko-Liisa Kellokumpu-Lehtinen, Peter Canney, Riikka Huovinen, Patric Neven, Henrik Lindman, Päivi Auvinen, Judith Fraser, Diana Ritchie, Paul Nyandoto
Publikováno v:
Cancer Research. 78:GS3-04
Background: The optimal duration of trastuzumab (T), when given together with chemotherapy and after chemotherapy as adjuvant treatment in patients with HER2+ breast cancer (BC), is unknown. Whilst the international standard is 12 months of T, the be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb9184c698dec5ee70822de9ac4d7e18
https://doi.org/10.1158/1538-7445.sabcs17-gs3-04
https://doi.org/10.1158/1538-7445.sabcs17-gs3-04
Autor:
Raija Ristamäki, Juha Kononen, Antti Jekunen, Pia Österlund, P. Halonen, Raija Kallio, Annika Ålgars, Renee Lindvall-Andersson, Laura Aroviita, Eila Lantto, Paul Nyandoto, Annamarja Lamminmäki, Arno Nordin, Ilmo Kellokumpu, Helena Isoniemi, Tuija Poussa, Maija-Leena Murashev, T. Salminen, Ali Ovissi, Leena-Maija Soveri
Publikováno v:
Journal of Clinical Oncology. 37:3517-3517
3517 Background: Resection of oligometastatic mCRC is curable in up to half and is probably underused in real-life oncology practice. In 2011, a prospective nationwide centralized evaluation of resectability was initiated to assess upfront and conver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c802adca0ce3362c112379d0fa9805e
https://doi.org/10.1200/jco.2019.37.15_suppl.3517
https://doi.org/10.1200/jco.2019.37.15_suppl.3517
Autor:
Heikki Joensuu, Vesa Kataja, Minna Tanner, Johan Ahlgren, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Leena Helle, Henrik Lindman, Päivi Auvinen, M. Leinonen, Greger Nilsson, Kenneth Villman, Arja Jukkola-Vuorinen, R. Kokko, Paul Nyandoto, Outi Saarni, Petri Bono
Publikováno v:
Acta Oncologica (Stockholm, Sweden)
Background. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. Patients and methods. One thousand and five
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa75fa15792305e60516ea932809dc25
https://doi.org/10.3109/0284186x.2013.820840
https://doi.org/10.3109/0284186x.2013.820840
Autor:
Petri Bono, Marjo Pajunen, Pirkko-Liisa Kellokumpu-Lehtinen, Raija Asola, Paula Poikonen, R. Kokko, Henrik Lindman, Päivi Auvinen, Vesa Kataja, Riikka Huovinen, Minna Tanner, Arja Jukkola-Vuorinen, Paul Nyandoto, M. Leinonen, Heikki Joensuu, Outi Paija, Kenneth Villman, Leena Helle, Johan Ahlgren, Greger Nilsson
Publikováno v:
Journal of Clinical Oncology. 30:11-18
Purpose Capecitabine is an active agent in the treatment of breast cancer. It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9eee084901a260a8b4969b9294d0a6a
https://doi.org/10.1200/jco.2011.35.4639
https://doi.org/10.1200/jco.2011.35.4639